Light Touch Technology’s ¥500 million May round funds clinical tests of its laser glucose sensor
The Osaka startup says its May round will fund clinical performance testing and mass-production work for its fingertip laser glucose sensor. The device is not approved, and the accuracy test detailed in its founder’s 2018 journal article involved four healthy volunteers.
Based on announcements from the company, its investor Tamron and the research institute QST; features in KIZUNA, the Japanese government’s public-relations magazine, and Highlighting Japan, another government publication; and a 2018 journal article by the company’s founder · Sources
Light Touch Technology Inc., an Osaka startup developing a laser sensor that reads blood glucose from a fingertip without a needle, raised ¥500 million in a Series B extension round it announced on May 11, 2026. The sum combines new shares taken up by the optics maker Tamron, JMTC Capital, Hiroshima Venture Capital and BP Capital with a subsidy from Kyoto Prefecture and a loan from The Kiyo Bank. The company, known as LTT, put its total funding to date at about ¥1.2 billion.
LTT said in its Japanese-language release that the money would pay for clinical performance testing of the sensor and for production engineering ahead of mass manufacturing, work it says will speed its path to regulatory approval and sales. The release gave no timetable for the testing. In January, KIZUNA, the Japanese government’s public-relations magazine, had written: “In 2026, full-scale clinical trials will begin, with the goal of receiving recognition as a medical device from the Ministry of Health, Labour and Welfare.” As of Nov. 19, LTT had not announced the start of those trials.
About 589 million adults aged 20 to 79 were living with diabetes in 2024, according to the International Diabetes Federation, which expects the number to reach 853 million by 2050. LTT is developing a portable sensor for people with diabetes and a stationary unit, the Carbo Health Sensor, meant for pharmacies, libraries and fitness centers; its website lists both as under development. A user rests a fingertip on the sensor for about five seconds, and the result is sent wirelessly to a smartphone, the company says.
Tamron, which is based in Saitama City, announced its investment on Feb. 2 without giving an amount. It said it would explore pairing LTT’s lasers with its own optical technology under a strategy of shifting “from imaging to measuring” and developing products in new fields.
How the laser reads glucose
Koichi Yamakawa, LTT’s founder and CEO, headed a laser research group at QST (National Institutes for Quantum Science and Technology), a Japanese government research agency, when the institute certified LTT as its first startup on July 5, 2017. The company was incorporated five days later.
His group built a palm-sized mid-infrared laser by combining a solid-state laser with optical parametric oscillation, a method that converts near-infrared laser light to longer, mid-infrared wavelengths. QST said in 2017 that brightness had been the obstacle: mid-infrared wavelengths can be chosen so that glucose absorbs them selectively, but ceramic heaters and other conventional sources give off too little of that light for accurate readings. Near-infrared light, the basis of more than 20 years of earlier attempts, carries only a faint glucose signal that proteins, fats and body temperature can drown out.
In a 2018 feature article for the Journal of the Japan Diabetes Society, Yamakawa wrote that at 9 micrometers, a wavelength where glucose absorbs strongly, the laser’s peak output was about a billion times that of conventional sources. The measurement works by reflection, the article explains: a detector collects the light that scatters back out of the fingertip, and the shortfall caused by glucose absorption is converted into a glucose value.
The published accuracy data
KIZUNA’s January feature described LTT’s method as “the first non-invasive blood glucose level measurement technology in the world to meet International Organization for Standardization (ISO) standards for measurement accuracy under certain conditions.” Tamron’s release names the standard as ISO 15197.
Yamakawa’s 2018 article made the ISO claim with the same qualifier and describes the test cited for it. Four healthy volunteers took part in repeated oral glucose tolerance tests on different days, and the laser readings were compared with those of a conventional fingerstick meter over glucose levels of 61 to 198 mg/dL. He reported that at least 95% of readings fell in zone A of a consensus error grid, which he equated with the ISO 15197:2013 requirement. He also wrote that clinical studies in people with diabetes were planned to show the method works across a wider range of glucose levels, and he listed his LTT shareholding as a conflict of interest. In March 2020, Highlighting Japan, another government publication, reported that a nonprofit supporting families affected by type 1 diabetes was helping the company gather and analyze measurement data.
The sensor does not yet have regulatory approval. Neither KIZUNA nor the May release reports accuracy results from people with diabetes, and neither gives a date for an approval filing or a launch. Earlier targets have passed: the 2018 article said LTT was aiming to commercialize the sensor in fiscal 2021, and the 2020 Highlighting Japan report put the start of sales in 2022, after ministry approval.
Sources
- PR TIMES prtimes.jp
- KIZUNA — JapanGov, the Official Website of the Government of Japan japan.go.jp
- J-STAGE jstage.jst.go.jp
- Light Touch Technology light-tt.co.jp
- QST qst.go.jp
- Light Touch Technology · product light-tt.co.jp
- Tamron tamron.com
- International Diabetes Federation idf.org
- Highlighting Japan gov-online.go.jp
Every article lists its sources · Editorial standards · Corrections: press@japantechdesk.com
Next storyYamagata University’s Benibana-Sat engineering model completes vibration and thermal-vacuum tests